Generation Bio is a biotechnology company developing a breakthrough class of gene therapy to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWaveTM technology, which delivers durable, high levels of gene expression and can be titrated to effect and redosed to sustain impact over a lifetime.

Foresite Capital recognizes the paradigm shift gene therapy is having in medicine and sees Generation Bio as a leader in these efforts with unique and proprietary insights.